CAJ | 학술논문

目的：探讨血浆中EB病毒阳性在评价结外NK/T细胞淋巴瘤近期疗效和远期疗效中的临床意义。方法：收集2011年1月至2014年4月郑州大学第一附属医院经病理及免疫组化确诊为结外NK/T细胞淋巴瘤的患者109例，应用qRT-PCR方法检测其血浆中EBV-DNA拷贝数，比较EBV阴性和EBV阳性患者对治疗疗效与预后的差异。结果：109例结外NK/T细胞淋巴瘤患者，53例阳性患者中有34例（64.2%）为晚期（Ⅲ～Ⅳ期），56例阴性患者中22例（39.3%）为晚期（Ⅲ～Ⅳ期），EBV阳性组中伴有B症状33例（62.3%），阴性组患者21例（37.5%），EBV阴性患者与EBV阳性患者在分期及B症状方面均具有统计学意义（P<0.05）。34例（60.7%）EBV阴性结外NK/T细胞淋巴瘤患者达到客观缓解率，显著高于EBV阳性患者的客观缓解率（22例，41.5%）（P<0.05）。EBV阴性组与EBV阳性组相比，其2年无进展生存期更高（P<0.05）。结论：检测结外NK/T细胞淋巴瘤患者血浆中EB病毒对评价其近期疗效及2年无进展生存期具有重要的临床意义。
목적：탐토혈장중EB병독양성재평개결외NK/T세포림파류근기료효화원기료효중적림상의의。방법：수집2011년1월지2014년4월정주대학제일부속의원경병리급면역조화학진위결외NK/T세포림파류적환자109례，응용qRT-PCR방법검측기혈장중EBV-DNA고패수，비교EBV음성화EBV양성환자대치료료효여예후적차이。결과：109례결외NK/T세포림파류환자，53례양성환자중유34례（64.2%）위만기（Ⅲ～Ⅳ기），56례음성환자중22례（39.3%）위만기（Ⅲ～Ⅳ기），EBV양성조중반유B증상33례（62.3%），음성조환자21례（37.5%），EBV음성환자여EBV양성환자재분기급B증상방면균구유통계학의의（P<0.05）。34례（60.7%）EBV음성결외NK/T세포림파류환자체도객관완해솔，현저고우EBV양성환자적객관완해솔（22례，41.5%）（P<0.05）。EBV음성조여EBV양성조상비，기2년무진전생존기경고（P<0.05）。결론：검측결외NK/T세포림파류환자혈장중EB병독대평개기근기료효급2년무진전생존기구유중요적림상의의。
Objective:To investigate the clinical significance of detecting Epstein Barr virus (EBV) infection in evaluating recent curative and long-term effects in patients with extranodal natural killer (NK)/T-cell lymphoma. Methods:The EBV-DNA copies in the plasma of 109 patients, who were pathologically and immunohistochemically diagnosed with extranodal natural killer/T-cell lymphoma in the First Affiliated Hospital of Zhengzhou University between January 2011 and April 2014, were monitored via quantitative re-al-time polymerase chain reaction. Subsequently, the difference in recent curative and long-term effects between EBV positive and EBV negative patients was compared. Results:Among the 109 patients with extranodal NK/T-cell lymphoma, 34 (64.2%) cases of EBV posi-tive patients were at the advanced stage (Ⅲ~Ⅳ stages), and 22 (39.3%) cases of EBV negative patients were at the terminal stage (Ⅲ~Ⅳstages). EBV positive patients who accompanied by B symptoms were 33 (62.3%) , and there were 21 (37.5%) cases with B symptoms in EBV negative patients, the differences between stages and B symptoms were statistically significant. The attained objec-tive response rate of the EBV-DNA negative patients (34, 60.7%) was significantly higher than that of the EBV-DNA positive patients (22, 41.5%) (P<0.05). Similarly, the 2-year progression-free survival (PFS) rate of EBV negative patients was better than that of EBV positive patients (P<0.05). Conclusion:Detecting EBV in plasma has clinical significance in evaluating the recent curative effect and the 2-year PFS rate in patients diagnosed with extranodal NK/T-cell lymphoma.